{"id": "267234", "url": "https://fevir.net/resources/Evidence/267234", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"], "versionId": "9", "lastUpdated": "2025-12-11T20:35:21.032Z"}, "name": "NCT03421379_secondaryOutcomeMeasure_0_OG000", "title": "Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "citeAs": "Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267234. Revised 2025-12-11. Available at: https://fevir.net/resources/Evidence/267234. Computable resource at: https://fevir.net/resources/Evidence/267234#json.", "status": "active", "contact": [{"telecom": [{"value": "support@computablepublishing.com", "system": "email"}]}], "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "publisher": "Computable Publishing LLC", "statistic": [{"quantity": {"unit": "milligram/deciliter (mg/dL)", "value": 113}, "sampleSize": {"knownDataCount": 71}, "statisticType": {"coding": [{"code": "STATO:0000396", "system": "https://fevir.net/sevco", "display": "geometric mean"}]}, "attributeEstimate": [{"type": {"text": "Geometric Coefficient of Variation"}, "quantity": {"unit": "milligram/deciliter (mg/dL)", "value": 32}}]}], "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"code": "ACSN", "system": "http://terminology.hl7.org/CodeSystem/v2-0203", "display": "Accession ID"}]}, "value": "267234", "system": "https://fevir.net/FOI", "assigner": {"display": "Computable Publishing LLC"}}, {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-secondaryOutcomeMeasure-0--OG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "resourceType": "Evidence", "variableDefinition": [{"note": [{"text": "Outcome Measure Population Description: All randomized patients who receive at least 1 dose of the study drug and have evaluable PD data."}, {"text": "Outcome Measure Denominator Units: Participants"}], "observed": {"display": "A single dose of 3 mg glucagon nasal powder was administered intranasally", "identifier": {"type": {"text": "ClinicalTrials.gov Outcome Measurement Group Id"}, "value": "OG000"}}, "description": "Glucagon Nasal Powder", "variableRole": "population"}, {"observed": {"type": "EvidenceVariable", "display": "Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration -  (NCT03421379)", "reference": "EvidenceVariable/267227", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-secondaryOutcome-0", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "variableRole": "outcome"}], "description": "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide."}